Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases.
Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.
Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $131.5M
Founded date: 2015
Investors 5
| Date | Name | Website |
| - | ShangPharm... | spiivc.com |
| - | Omega Fund... | omegafunds... |
| - | Timefolio ... | timefolioc... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | SR One | srone.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.09.2018 | Series B | $80M | - |
| 30.06.2016 | Series A | $51.5M | SR One |
Mentions in press and media 14
| Date | Title | Description | Source |
| 05.03.2024 | Morphic to Participate in March Investor Conferences | - | globenewsw... |
| 03.05.2023 | Morphic Therapeutic Announces Pricing of $240.0 Million Publ... | - | globenewsw... |
| 18.10.2018 | Morphic partners with investor AbbVie on integrin inhibitor ... | Last month, Morphic closed an $80 million Series B financing – in which AbbVie Ventures participated... | medcitynew... |
| 26.09.2018 | Term Sheet — Wednesday, September 26 | THE UNRAVELING Good morning, Term Sheet readers. Paid Content Securing the enterprise without bounda... | fortune.co... |
| 26.09.2018 | Morphic Therapeutic Raises $80M in Series B Financing | Morphic Therapeutic, a Waltham, Mass.-based biotechnology company developing a new generation of ora... | finsmes.co... |
| 26.09.2018 | Morphic Therapeutic Announces $80M | WALTHAM, MA, Morphic Therapeutic announced today that it has completed a $80 million Series B fina... | vcnewsdail... |
| 25.09.2018 | Morphic raises $80M in Series B round to fund oral integrin ... | “With compelling preclinical data across a number of programs, we are accelerating our advance into ... | medcitynew... |
| 30.06.2016 | Biotechnology Company Morphic Therapeutic Closes $51.5M Seri... | Morphic Therapeutic, a Waltham, MA-based biotechnology company developing a new generation of oral i... | finsmes.co... |
| 30.06.2016 | Morphic Therapeutic Nets $51.5M | WALTHAM, MA, Morphic Therapeutic, a biotechnology company developing a new generation of oral inte... | vcnewsdail... |
| 30.06.2016 | Morphic Therapeutic Raises $51.5M Series A Co-Led by SR One ... | WALTHAM, Mass.--(BUSINESS WIRE)--Morphic Therapeutic, a biotechnology company developing a new gener... | citybizlis... |
Show more